Skip to main content

Advertisement

Log in

Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety

  • Review Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

We did a systematic review and meta-analysis on the efficacy and safety of the anti-TNF drugs adalimumab, etanercept, golimumab and infliximab used in psoriatic arthritis (PsA) adult treatment. Additionally, we present results of anti-TNF use in real life settings. We searched Embase, Medline, Cochrane Central and LILACS, from inception to 11/08/2013, for studies comparing anti-TNFs with each other or with controls. We included nine randomized controlled trials and six observational studies. ACR20, ACR50, PsARC and PASI75 responses were achieved by more users of anti-TNF than control after up to 24 weeks of treatment. More participants who used etanercept and infliximab achieved ACR70. After all patients originally randomized to anti-TNF or placebo had used anti-TNF for at least 24 weeks, we observed difference only with regard to ACR70 response. Radiographic end points were achieved by more patients in anti-TNF group, and they seem to be time dependent—the longer patients use the drug the better the results. Etanercept and infliximab had worse results on application site reactions, but in general anti-TNF drugs in the regimens studied were as safe as control/placebo. There seems to be no difference in efficacy and effectiveness among anti-TNFs, but superiority head-to-head studies are still needed. Meanwhile, other factors should be taken into account in the choice of medication, such as costs and patient convenience.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gottlieb A, Korman NJ, Gordon KB et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58(5):851–864

    Article  PubMed  Google Scholar 

  2. Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcomes. Ann Rheum Dis 64(suppl 2):ii14–ii17

    PubMed  PubMed Central  Google Scholar 

  3. Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 45:151–158

    Article  CAS  Google Scholar 

  4. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25. doi:10.1186/1477-7525-7-25

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. J Clin Pharm Ther 35(12):680–689

    Google Scholar 

  6. Rosen C, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman D (2012) Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 51:571–576

    Article  PubMed  Google Scholar 

  7. Gossec L, Smolen J, Gaujoux-Viala CL et al (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Arthritis Rheum 71:4–12

    CAS  Google Scholar 

  8. Pereda C, Nishishinya M, Martinez Lopez J, Carmona L (2012) Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Clin Exp Rheumatol 30(2):282–289

    PubMed  Google Scholar 

  9. Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane collaboration. www.cochrane-handbook.org

  10. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Brit Med J 339:b2700

    Article  PubMed  PubMed Central  Google Scholar 

  11. Felson DT, Anderson JJ, Boers M et al (1995) American-College-of-Rheumatology preliminary definition of improvement in rheumatoid-arthritis. Arthritis Rheum 38(6):727–735

    Article  PubMed  CAS  Google Scholar 

  12. Clegg DO, Reda DJ, Mejias E et al (1966) Comparision of sulfassalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 39:2013–2020

    Article  Google Scholar 

  13. Fransen J, van Riel PLCM (2005) The disease activity score and the EULAR response criteria. ClinExpRheumatol 23(Suppl. 39):S93–S99

    CAS  Google Scholar 

  14. Fredriksson T, Pettersson U (1978) Severe psoriasis oral therapy with a new retinoid. Dermatologica 157:238–244

    Article  PubMed  CAS  Google Scholar 

  15. Van der Heijde DMFM, van‘t Hof MA, van Riel PLCM et al (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 9:789–793

    PubMed  CAS  Google Scholar 

  17. Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey: I. Conceptual framework and item selection. Med Care 30:473–483

    Article  PubMed  Google Scholar 

  18. McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263

    Article  PubMed  CAS  Google Scholar 

  19. Cella D, Webster K (1997) Linking outcomes management to quality-of-life measurement. Oncology 11:232–235

    PubMed  CAS  Google Scholar 

  20. Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence:terminology and definitions. Value Health 11(1):44–47

    Article  PubMed  Google Scholar 

  21. Woodroffe R, Yao GL, Meads C et al (2005) Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Asses 9(21):1–179 (iii–iv)

    CAS  Google Scholar 

  22. Higgins JPT, Altman AD, Sterne JAC (2012) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochrane-handbook.org

  23. Hartling L, Hamm M, Milne A et al (2012) Validity and inter-rater reliability testing of quality assessment instruments [internet]. Appendix E, decision rules for application of the Newcastle-Ottawa Scale. Agency for Healthcare Research and Quality (US), Rockville (MD). http://www.ncbi.nlm.nih.gov/books/NBK92291/

  24. Landis JR, Koch GG (1997) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174

    Article  Google Scholar 

  25. Deeks JJ, Higgins J, Altman DG (2012) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochrane-handbook.org

  26. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52. doi:10.1186/ar2670

    Article  PubMed  PubMed Central  Google Scholar 

  27. Saad AA, Ashcroft DM, Watson KD et al (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 49:697–705

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Saad AA, Ashcroft DM, Watson KD et al (2010) Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthrit Care Res 62(3):345–353

    Article  Google Scholar 

  29. Virkki LM, Sumathikutty BC, Arnio MA et al (2010) Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years. J Rheumatol 37:2362–2368

    Article  PubMed  Google Scholar 

  30. Saougou I, Markatseli TE, Papagoras C et al (2011) Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 40:398–406

    Article  PubMed  CAS  Google Scholar 

  31. Chastek B, Prairie E, Watson C et al (2012) Tumor necrosis factor-blocker therapy persistence, gaps, and switching among patients with psoriatic arthritis. J Am Acad Dermatol 66(4):206 (Suppl 1)

    Google Scholar 

  32. Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR (2013) Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat 24:369–373

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. Mease P, Gladman D, Ritchlin C et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 52(10):3279–3289

    Article  PubMed  CAS  Google Scholar 

  34. Gladman D, Mease P, Cifaldi M, Perdok R, Sasso E, Medich J (2007) Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 66:163–168

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Gladman D, Mease P, Ritchlin C et al (2007) Adalimumab for long-term treatment of psoriatic arthritis. Arthritis Rheum 56(2):476–488

    Article  PubMed  CAS  Google Scholar 

  36. Mease P, Ory P, Sharp J et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702–709

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Genovese M, Mease P, Thomason G et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1–5

    Google Scholar 

  38. Mease P, Goffe B, Metz J, Vanderstoep A, Finck B, Burge D (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390

    Article  PubMed  CAS  Google Scholar 

  39. Mease P, Kivitz A, Burch F et al (2004) Etanercept treatment of psoriatic arthritis. Arthritis Rheum 50(7):2264–2272

    Article  PubMed  CAS  Google Scholar 

  40. Mease P, Kivitz A, Burch F et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33(4):712–721

    PubMed  CAS  Google Scholar 

  41. Mease P, Woolley M, Singh A, Tsuji W, Dunn M, Chou C-F (2010) Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 37(6):1221–1227

    Article  PubMed  CAS  Google Scholar 

  42. Kavanaugh A, Mcinnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum 60(4):976–986

    Article  PubMed  CAS  Google Scholar 

  43. Kavanaugh A, Van Der Heijde D, Mcinnes I et al (2012) Golimumab in psoriatic arthritis. Arthritis Rheum 64(8):2504–2517

    Article  PubMed  CAS  Google Scholar 

  44. Kavanaugh A, Mcinnes I, Mease P et al (2012) Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 0:1–10

    Google Scholar 

  45. Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study. J Rheumatol 39(suppl. 89):90–93

    Google Scholar 

  46. Kavanaugh A, McInnes IB, Krueger GG et al (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthrit Care Res 65(10):1666–1673

    CAS  Google Scholar 

  47. Antoni C, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab theray for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 52(4):1227–1236

    Article  PubMed  CAS  Google Scholar 

  48. Kavanaugh A, Antoni C, Gladman D et al (2006) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65:1038–1043

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Antoni C, Kavanaugh A, van der Heijde D et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35(5):869–876

    PubMed  CAS  Google Scholar 

  50. Antoni C, Krueger G, Vlam K et al (2005) Inflixmab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  51. Kavanaugh A, Antoni C, Krueger G, Yan S, Bala M, Dooley L, Beautler A, Guzza C, Gladman D (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65:471–477

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  52. Kavabaungh A, Anatoni C, Mease P, Gladman D, Yan S, Bala M, Dooley L, Beutler A, GuzzoU C, Krueger G (2006) Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 33(11):2254–2259

    Google Scholar 

  53. van der Heijde D, Kavanaugh A, Gladman D et al (2007) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment. Arthritis Rheum 56(8):2698–2707

    Article  PubMed  Google Scholar 

  54. Kavanaugh A, Krueger G, Beutler A et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66:498–505

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  55. Baranauskaite A, Raffayavá H, Kungurov N et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541–548

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  56. Atteno M, Peluso R, Costa L, Padula S, Caso F, Iervolino S, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399–403

    Article  PubMed  Google Scholar 

  57. Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673

    Article  PubMed  Google Scholar 

  58. Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227

    Article  PubMed  CAS  Google Scholar 

  59. Ravindran V, Scott DL, Choy EH (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855–859

    Article  PubMed  CAS  Google Scholar 

  60. Saad AA, Symmons DP, Noyce PR et al (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35:883–890

    PubMed  CAS  Google Scholar 

  61. Woolacott NF, Khadjesari ZC, Bruce IN et al (2006) Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 24:587–593

    PubMed  CAS  Google Scholar 

  62. Ash Z, Gaujoux-Viala C, Gossec L (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71:319–326

    Article  PubMed  CAS  Google Scholar 

  63. Finckh A, Liang MH, Mugica C (2006) Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55(6):864–872

    Article  PubMed  Google Scholar 

  64. Coates LC, Navarro-Coy N, Brown SR et al (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101. doi:10.1186/1471-2474-14-101

    Article  PubMed  PubMed Central  Google Scholar 

  65. Coates LC, Moverley AR, McParland L et al (2013) Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthritis Rheum 65(10, supplement):S346

    Google Scholar 

  66. NICE (2011) NICE technology appraisal guidance 220 Golimumab for the treatment of psoriatic arthritis. www.nice.org.uk/guidance/TA220

  67. NICE (2013) NICE technology appraisal guidance 199. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review of technology appraisal guidance 104 and 125). www.nice.org.uk/guidance/TA199

  68. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med 4(6):e184. doi:10.1371/journal.pmed.0040184

    Article  PubMed  PubMed Central  Google Scholar 

  69. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167. doi:10.1136/bmj.326.7400.1167

    Article  PubMed  PubMed Central  Google Scholar 

  70. Lubrano E, Marchesoni A, Olivieri I et al (2009) The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 27:977–980

    PubMed  CAS  Google Scholar 

  71. Coates L, Tillett W, Chandler D (2012) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology first published online 25 July 2013. doi:10.1093/rheumatology/ket187

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lívia Lovato Pires Lemos.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lemos, L.L.P., de Oliveira Costa, J., Almeida, A.M. et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 34, 1345–1360 (2014). https://doi.org/10.1007/s00296-014-3006-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3006-2

Keywords

Navigation